908 Devices (MASS) Set to Announce Earnings on Tuesday

908 Devices (NASDAQ:MASSGet Rating) is scheduled to be releasing its earnings data before the market opens on Tuesday, May 10th. Analysts expect 908 Devices to post earnings of ($0.30) per share for the quarter. 908 Devices has set its FY 2022 guidance at EPS.Persons that are interested in participating in the company’s earnings conference call can do so using this link.

908 Devices (NASDAQ:MASSGet Rating) last posted its quarterly earnings results on Monday, March 7th. The company reported ($0.12) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.18) by $0.06. 908 Devices had a negative return on equity of 14.85% and a negative net margin of 52.53%. The company had revenue of $15.84 million for the quarter, compared to analysts’ expectations of $15.13 million. During the same period last year, the firm earned ($0.60) earnings per share. 908 Devices’s quarterly revenue was up 177.1% on a year-over-year basis. On average, analysts expect 908 Devices to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

MASS opened at $18.32 on Tuesday. The business’s 50-day simple moving average is $18.33 and its 200-day simple moving average is $21.83. The company has a debt-to-equity ratio of 0.07, a quick ratio of 16.51 and a current ratio of 17.05. 908 Devices has a one year low of $12.60 and a one year high of $53.66. The stock has a market capitalization of $572.21 million, a P/E ratio of -22.90 and a beta of 2.36.

A number of equities analysts recently issued reports on the company. Zacks Investment Research lowered 908 Devices from a “buy” rating to a “hold” rating in a report on Thursday, March 10th. SVB Leerink lowered their price target on 908 Devices from $40.00 to $30.00 and set an “outperform” rating on the stock in a report on Tuesday, March 8th.

In other 908 Devices news, VP John Kenneweg sold 19,881 shares of 908 Devices stock in a transaction that occurred on Friday, March 18th. The stock was sold at an average price of $20.06, for a total value of $398,812.86. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CTO Christopher D. Brown sold 9,829 shares of the business’s stock in a transaction that occurred on Tuesday, April 12th. The stock was sold at an average price of $20.06, for a total value of $197,169.74. Following the sale, the chief technology officer now directly owns 959,083 shares in the company, valued at approximately $19,239,204.98. The disclosure for this sale can be found here. Insiders sold a total of 79,829 shares of company stock worth $1,560,557 in the last ninety days. 51.10% of the stock is owned by corporate insiders.

Large investors have recently made changes to their positions in the company. Bank of America Corp DE boosted its stake in shares of 908 Devices by 31.5% during the 4th quarter. Bank of America Corp DE now owns 22,823 shares of the company’s stock worth $591,000 after acquiring an additional 5,463 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in shares of 908 Devices by 126.7% during the 4th quarter. JPMorgan Chase & Co. now owns 17,972 shares of the company’s stock worth $465,000 after acquiring an additional 10,044 shares in the last quarter. Susquehanna International Group LLP boosted its stake in shares of 908 Devices by 64.6% during the 4th quarter. Susquehanna International Group LLP now owns 17,610 shares of the company’s stock worth $456,000 after acquiring an additional 6,910 shares in the last quarter. Rhumbline Advisers boosted its stake in shares of 908 Devices by 40.6% during the 4th quarter. Rhumbline Advisers now owns 12,345 shares of the company’s stock worth $319,000 after acquiring an additional 3,567 shares in the last quarter. Finally, Wells Fargo & Company MN boosted its stake in shares of 908 Devices by 1,721.3% during the 4th quarter. Wells Fargo & Company MN now owns 11,092 shares of the company’s stock worth $287,000 after acquiring an additional 10,483 shares in the last quarter. 79.24% of the stock is currently owned by institutional investors and hedge funds.

908 Devices Company Profile (Get Rating)

908 Devices Inc, a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry (Mass Spec) devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, industrial biotech, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of gas, liquid, and solid materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and ZipChip solution, a plug-and-play, high-resolution separation platform that optimizes Mass Spec sample analysis.

See Also

Earnings History for 908 Devices (NASDAQ:MASS)

Receive News & Ratings for 908 Devices Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 908 Devices and related companies with MarketBeat.com's FREE daily email newsletter.